Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy

NCT01256632 is registered in ClinicalTrials.gov with Vision Research Foundation as lead sponsor.

NCT NCT01256632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01256632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
Lead sponsor
Vision Research Foundation
Phase
Not applicable
Overall status
Completed
Start date
October 31, 2007
Completion date
October 31, 2010
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal neovascularization